Dianthus Therapeutics, Inc.

Contributing Author

Recent Articles by Dianthus Therapeutics, Inc.

Nov-05	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results DNTH GlobeNewswire
Nov-04	Dianthus Therapeutics to Participate in Four Investor Conferences During November DNTH GlobeNewswire
Oct-29	Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting DNTH GlobeNewswire
Oct-16	Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases DNTH GlobeNewswire
Oct-02	Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting DNTH GlobeNewswire
Sep-11	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares DNTH GlobeNewswire
Sep-09	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering DNTH GlobeNewswire
Sep-08	Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering DNTH GlobeNewswire
Sep-08	Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile DNTH GlobeNewswire
Sep-07	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis DNTH GlobeNewswire
Aug-07	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results DNTH GlobeNewswire
May-29	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference DNTH GlobeNewswire
May-22	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors DNTH GlobeNewswire
May-12	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results DNTH GlobeNewswire
May-05	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September DNTH GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.